“We use cookies on this website to enhance your user experience and to personalise content. By clicking any link or continuing to use our Website you agree to our cookies as per our Privacy Policy. Read More” Ok, I agree

Dexamethasone Sodium Phosphate (Dexamethasone Sodium Phosphate)

Trade Name : Dexamethasone Sodium Phosphate

Medical Purchasing Solutions, LLC

INJECTION

Strength 4 mg/mL

DEXAMETHASONE SODIUM PHOSPHATE Corticosteroid [EPC],Corticosteroid Hormone Receptor Agonists [MoA]

Delivery Process

Submit a Request

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

We’ll Get in Touch

Once we review your request, we’ll send you an estimated price for the medicine within 2-5 days.

Confirmation and Payment

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

Submit a Request

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

Product information is meant for

Wholesalers Suppliers Exporters Doctors MOH Tender Supplies Hospitals Brand CROs Comparator Supplies Generic Cooperate Sourcing Individual Patients Indian Institutional Buyers

Disclaimer

Trade Marks displayed in compliance with provisions of: Trademark Act, 1999 u/s 30 and 30 (1) of "Fair use"

GNH India is WHO GDP and ISO 9001 2015 Certified Pharmaceutical Wholesaler/ Supplier/ Exporters/ Importer from India of Dexamethasone Sodium Phosphate (Dexamethasone Sodium Phosphate) which is also known as Dexamethasone Sodium Phosphate and Manufactured by Medical Purchasing Solutions, LLC. It is available in strength of 4 mg/mL per ml. Read more

Dexamethasone Sodium Phosphate (Dexamethasone Sodium Phosphate) is supplied for Tenders/ Emergency imports/ Un - licensed, Specials, Orphan drug/ Name patient line/ RLD supplies/ Reference listed drugs/ Comparator Drug/ Bio-Similar/ Innovator samples For Clinical trials.  Click to know price.     Read less

Packaging and Delivery

Validated Cold Chain Shipment

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

Inquire directly from our website and get 5% off on any medicine!

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

Read more

About GNH

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

Read more
  • No data
  • Dexamethasone sodium phosphate injection, USP is a water-soluble inorganic ester of dexamethasone which produces a rapid response even when injected intramuscularly.
  • Dexamethasone sodium phosphate, a synthetic adrenocortical steroid, is a white or slightly yellow crystalline powder. It is freely soluble in water and is exceedingly hygroscopic. The molecular weight is 516.41. It is designated chemically as 9-fluoro-11u03b2,17-dihydroxy-16u03b1-methyl-21-(phosphonooxy)pregna-1,4-diene-3, 20-dione disodium salt.
  • The molecular formula is: Cn n n Hn n n FNan n n On n n P and the structural formula is:n nn
  • Dexamethasone Sodium Phosphate Injection is a sterile solution of dexamethasone sodium phosphate for intravenous and intramuscular use. The 4 mg/mL strength may also be used for intra-articular, intralesional and soft tissue administration.
  • Each mL of Dexamethasone Sodium Phosphate Injection 4 mg/mL contains dexamethasone sodium phosphate, equivalent to 4 mg dexamethasone phosphate or 3.33 mg dexamethasone. Inactive ingredients per mL: 1 mg sodium sulfite anhydrous, 19.4 mg sodium citrate anhydrous and 10.42 mg (0.01 mL) benzyl alcohol (preservative) in Water for Injection.
  • Each mL of Dexamethasone Sodium Phosphate Injection 10 mg/mL contains dexamethasone sodium phosphate, equivalent to 10 mg dexamethasone phosphate or 8.33 mg dexamethasone. Inactive ingredients per mL: 1.5 mg sodium sulfite anhydrous, 16.5 mg sodium citrate anhydrous and 10.42 mg (0.01 mL) benzyl alcohol (preservative) in Water for Injection.
  • The pH of both concentrations is 7.0-8.5; sodium hydroxide and/or citric acid used, if needed, for pH adjustment. Sealed under nitrogen.
  • Naturally occurring glucocorticoids (hydrocortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs are primarily used for their potent anti-inflammatory effects in disorders of many organ systems.
  • Glucocorticoids cause profound and varied metabolic effects. In addition, they modify the bodyu2019s immune responses to diverse stimuli.
  • Arrayn- Array
  • 1. n n n n
  • Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance)
  • Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used)
  • Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful
  • Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected
  • Congenital adrenal hyperplasia
  • Nonsuppurative thyroiditis
  • Hypercalcemia associated with cancer
  • 2. n- Array
  • As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in:
  • Post-traumatic osteoarthritis
  • Synovitis of osteoarthritis
  • Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy)
  • Acute and subacute bursitis
  • Epicondylitis
  • Acute nonspecific tenosynovitis
  • Acute gouty arthritis
  • Psoriatic arthritis
  • Ankylosing spondylitis
  • 3. n- Array
  • During an exacerbation or as maintenance therapy in selected cases of:
  • Systemic lupus erythematosus
  • Acute rheumatic carditis
  • 4. n- Array
  • Pemphigus
  • Severe erythema multiforme (Stevens-Johnson Syndrome)
  • Exfoliative dermatitis
  • Bullous dermatitis herpetiformis
  • Severe seborrheic dermatitis
  • Severe psoriasis
  • Mycosis fungoides
  • 5. n- Array
  • Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in:
  • Bronchial asthma
  • Contact dermatitis
  • Atopic dermatitis
  • Serum sickness
  • Seasonal or perennial allergic rhinitis
  • Drug hypersensitivity reactions
  • Urticarial transfusion reactions
  • Acute noninfectious laryngeal edema (epinephrine is the drug of first choice)
  • 6. n- Array
  • Severe acute and chronic allergic and inflammatory processes involving the eye, such as:
  • Herpes zoster ophthalmicus
  • Iritis, iridocyclitis
  • Chorioretinitis
  • Diffuse posterior uveitis and choroiditis
  • Optic neuritis
  • Sympathetic ophthalmia
  • Anterior segment inflammation
  • Allergic conjunctivitis
  • Allergic corneal marginal ulcers
  • Keratitis
  • 7. n- Array
  • Tou00a0tide the patient over a critical period of the disease in:
  • Ulcerative colitis (systemic therapy)
  • Regional enteritis (systemic therapy)
  • 8. n- Array
  • Symptomatic Sarcoidosis
  • Berylliosis
  • Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate anti-tuberculosis chemotherapy
  • Loeffler's syndrome not manageable by other means
  • Aspiration pneumonitis
  • 9. n- Array
  • Acquired (autoimmune) hemolytic anemia
  • Idiopathic thrombocytopenic purpura in adults (I.V. only; I.M. administration is contraindicated)
  • Secondary thrombocytopenia in adults
  • Erythroblastopenia (RBC anemia)
  • Congenital (erythroid) hypoplastic anemia
  • 10. n- Array
  • For palliative management of:
  • Leukemias and lymphomas in adults
  • Acute leukemia of childhood
  • 11. n- Array
  • To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus
  • 12. n- Array
  • Acute exacerbations of multiple sclerosis
  • 13. n- Array
  • Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate anti-tuberculosis chemotherapy
  • Trichinosis with neurologic or myocardial involvement
  • Diagnostic testing of adrenocortical hyperfunction
  • Cerebral edema of diverse etiologies in conjunction with adequate neurological evaluation and management.
  • Arrayn- B. Intra-articular or soft tissue administration.
  • Synovitis of osteoarthritis
  • Rheumatoid arthritis
  • Acute and subacute bursitis
  • Acute gouty arthritis
  • Epicondylitis
  • Acute nonspecific tenosynovitis
  • Post-traumatic osteoarthritis
  • Arrayn- Array
  • Keloids
  • Localized hypertrophic, infiltrated, inflammatory lesions of: lichen planus, psoriatic plaques, granuloma annulare, and lichen simplex chronicus (neurodermatitis)
  • Discoid lupus erythematosus
  • Necrobiosis lipoidica diabeticorum
  • Alopecia areata
  • They also may be useful in cystic tumors of an aponeurosis tendon (ganglia).
  • Systemic fungal infections.
  • No data
  • Drug-induced secondary adrenocortical insufficiency may be minimized by gradual reduction of dosage. This type of relative insufficiency may persist for months after discontinuation of therapy; therefore, in any situation of stress occurring during that period, hormone therapy should be reinstituted. Since mineralocorticoid secretion may be impaired, salt and/or a mineralocorticoid should be administered concurrently.
  • There is an enhanced effect of corticosteroids in patients with hypothyroidism and in those with cirrhosis.
  • Corticosteroids should be used cautiously in patients with ocular herpes simplex for fear of corneal perforation.
  • The lowest possible dose of corticosteroid should be used to control the condition under treatment, and when reduction in dosage is possible, the reduction must be gradual.
  • Psychic derangements may appear when corticosteroids are used ranging from euphoria, insomnia, mood swings, personality changes, and severe depression to frank psychotic manifestations. Also, existing emotional instability or psychotic tendencies may be aggravated by corticosteroids.
  • Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia.
  • Steroids should be used with caution in nonspecific ulcerative colitis, if there is a probability of impending perforation, abscess, or other pyogenic infection, also in diverticulitis, fresh intestinal anastomoses, active or latent peptic ulcer, renal insufficiency, hypertension, osteoporosis, and myasthenia gravis.
  • Growth and development of infants and children on prolonged corticosteroid therapy should be carefully followed.
  • Patients who are on immunosuppressant doses of corticosteroids should be warned to avoid exposure to chickenpox or measles and, if exposed, to obtain medical advice.
  • Intra-articular injection of a corticosteroid may produce systemic as well as local effects.
  • Appropriate examination of any joint fluid present is necessary to exclude a septic process.
  • A marked increase in pain accompanied by local swelling, further restriction of joint motion, fever, and malaise are suggestive of septic arthritis. If this complication occurs and the diagnosis of sepsis is confirmed, appropriate antimicrobial therapy should be instituted.
  • Local injection of a steroid into a previously infected joint is to be avoided. Corticosteroids should not be injected into unstable joints.
  • Although controlled clinical trials have shown corticosteroids to be effective in speeding the resolution of acute exacerbations of multiple sclerosis they do not show that they affect the ultimate outcome or natural history of the disease. The studies do show that relatively high doses of corticosteroids are necessary to demonstrate a significant effect. (See n n n ).n nn
  • Since complications of treatment with glucocorticoids are dependent on the size of the dose and the duration of treatment a risk/benefit decision must be made in each individual case as to dose and duration of treatment and as to whether daily or intermittent therapy should be used.
  • Arrayn- Fluid and electrolyte disturbances:
  • Sodium retention
  • Fluid retention
  • Congestive heart failure in susceptible patients
  • Potassium loss
  • Hypokalemic alkalosis
  • Hypertension
  • Arrayn- Musculoskeletal:
  • Muscle weakness
  • Steroid myopathy
  • Loss of muscle mass
  • Osteoporosis
  • Vertebral compression fractures
  • Aseptic necrosis of femoral and humeral heads
  • Pathologic fracture of long bones
  • Arrayn- Gastrointestinal:
  • Peptic ulcer with possible subsequent perforation and hemorrhage
  • Pancreatitis
  • Abdominal distention
  • Ulcerative esophagitis
  • Arrayn- Dermatological:
  • Impaired wound healing
  • Thin fragile skin
  • Facial erythema
  • Increased sweating
  • May suppress reactions to skin tests
  • Petechiae and ecchymoses
  • Arrayn- Neurological:
  • Convulsions
  • Increased intracranial pressure with papilledema (pseudotumor cerebri) usually after treatment
  • Vertigo
  • Headache
  • Arrayn- Ophthalmic:
  • Posterior subcapsular cataracts
  • Increased intraocular pressure
  • Glaucoma
  • Arrayn- Endocrine:
  • Menstrual irregularities
  • Development of cushingoid state
  • Suppression of growth in children
  • Secondary adrenocortical and pituitary unresponsiveness, particularly in times of stress, as in trauma, surgery, or illness
  • Decreased carbohydrate tolerance
  • Manifestations of latent diabetes mellitus
  • Increased requirements for insulin or oral hypoglycemic agents in diabetics
  • Arrayn- Metabolic:
  • Negative nitrogen balance due to protein catabolism
  • Arrayn- Miscellaneous:
  • Hyperpigmentation or hypopigmentation
  • Subcutaneous and cutaneous atrophy
  • Sterile abscess
  • Postinjection flare following intra-articular use
  • Charcot-like arthropathy
  • Itching, burning, tingling in the ano-genital region
  • Arrayn- Array
  • The initial dosage of Dexamethasone Sodium Phosphate Injection may vary from 0.50 mg/day to 9.0 mg/day depending on the specific disease entity being treated. In situations of less severity, lower doses will generally suffice while in selected patients higher initial doses may be required. Usually the parenteral dosage ranges are one-third to one-half the oral dose given every 12 hours. However, in certain overwhelming, acute, life-threatening situations, administration of dosages exceeding the usual dosages may be justified and may be in multiples of the oral dosages.
  • For the treatment of unresponsive shock high pharmacologic doses of this product are currently recommended. Reported regimens range from 1 to 6 mg/kg of body weight as a single intravenous injection to 40 mg initially followed by repeat intravenous injection every 2 to 6 hours while shock persists.
  • For the treatment of cerebral edema in adults an initial intravenous dose of 10 mg is recommended followed by 4 mg intramuscularly every six hours until maximum response has been noted. This regimen may be continued for several days postoperatively in patients requiring brain surgery. Oral dexamethasone, 1 to 3 mg t.i.d., should be given as soon as possible and dosage tapered off over a period of five to seven days. Nonoperative cases may require continuous therapy to remain free of symptoms of increased intracranial pressure. The smallest effective dose should be used in children, preferably orally. This may approximate 0.2 mg/kg/24 hours in divided doses.
  • In treatment of acute exacerbations of multiple sclerosis daily doses of 200 mg of prednisolone for a week followed by 80 mg every other day or 4u20138 mg dexamethasone every other day for 1 month have been shown to be effective.
  • The initial dosage should be maintained or adjusted until a satisfactory response is noted. If after a reasonable period of time there is a lack of satisfactory clinical response, Dexamethasone Sodium Phosphate Injection should be discontinued and the patient transferred to other appropriate therapy. It should be emphasized that dosage requirements are variable and must be individualized on the basis of the disease under treatment and the response of the patient.
  • After a favorable response is noted, the proper maintenance dosage should be determined by decreasing the initial drug dosage in small decrements at appropriate time intervals until the lowest dosage which will maintain an adequate clinical response is reached. It should be kept in mind that constant monitoring is needed in regard to drug dosage. Included in the situations which may make dosage adjustments necessary are changes in clinical status secondary to remissions or exacerbations in the disease process, the patientu2019s individual drug responsiveness and the effect of patient exposure to stressful situations not directly related to the disease entity under treatment. In this latter situation it may be necessary to increase the dosage of dexamethasone sodium phosphate injection, USP for a period of time consistent with the patientu2019s condition. If after a long-term therapy the drug is to be stopped, it is recommended that it be withdrawn gradually rather than abruptly.
  • Arrayn- B. Intra-articular, soft tissue or intralesional administration.
  • The dose for instrasynovial administration is usually 2 to 4 mg for large joints and 0.8 to 1 mg for small joints. For soft tissue and bursal injections a dose of 2 to 4 mg is recommended. Ganglia require a dose of 1 to 2 mg. A dose of 0.4 to 1 mg is used for injection into tendon sheaths. Injection into intervertebral joints should not be attempted at any time and hip joint injection cannot be recommended as an office procedure.
  • Intrasynovial and soft tissue injections should be employed only when affected areas are limited to 1 or 2 sites. It should be remembered that corticoids provide palliation only and that other conventional or curative methods of therapy should be employed when indicated.
  • Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
  • Frequency of injection usually ranges from once every 3 to 5 days to once every 2 to 3 weeks. Frequent intra-articular injection may cause damage to joint tissue.
  • Dexamethasone Sodium Phosphate Injection, USP is available in the following package:
  • 4 mg/mL
  • 1 mL vials packaged in 25s (NDC 0641-6145-25)
  • 5 mL vials packaged in 25s (NDC 0641-6146-25)
  • 10 mg/mL
  • 1 mL vials packaged in 25s (NDC 0641-0367-25)
  • Protect from light: Keep covered in carton until time of use. Store at 20u00b0-25u00b0C (68u00b0-77u00b0F), excursions permitted to 15u00b0-30u00b0C (59u00b0-86u00b0F) [See USP Controlled Room Temperature]. Avoid freezing. Do not use if solution is hazy or has a precipitate. Do not autoclave.
  • To report SUSPECTED ADVERSE REACTIONS, contact West-Ward Pharmaceuticals Corp. at 1-877-845-0689, or the FDA at 1-800-FDA-1088 or n n n n
  • For Product Inquiry call 1-877-845-0689.
  • Manufactured by:
  • WEST-WARDn n n A HIKMA COMPANYn n n Eatontown, NJ 07724 USAn nn
  • Revised November 2016
  • 462-331-05
  • VIAL LABEL
  • Rx onlyn- Dexamethasone n- Sodium Phosphaten n nInjection, USPn n n4 mg/mL n n- For IV, IM, Intralesional, n- Intra-articular or n- Soft Tissue Use n- Protect from Light
  • Arrayn- Array
  • OUTER PACKAGE
  • Arrayn- Array
  • NDC 71872-7164-1n n
  • 1 - 1 mL Vial
  • Dexamethasone n- Arrayn- Arrayn- Intralesional, n- Intra-articular or n- Soft Tissue Use
  • No data

Similar Products

Desogestrel And Ethinyl Estradiol (Emoquette)

Desogestrel And Ethinyl Estradiol (Emoquette)

Manufacturer: REMEDYREPACK INC.

Presentation: KIT

Strength:

Pack Size:

Diphenoxylate Hydrochloride And Atropine Sulfate (Diphenoxylate Hydrochloride And Atropine Sulfate)

Diphenoxylate Hydrochloride And Atropine Sulfate (Diphenoxylate Hydrochloride And Atropine Sulfate)

Manufacturer: REMEDYREPACK INC.

Presentation: TABLET

Strength: 2.5; .025 mg/1; mg/1

Pack Size:

Fluoxetine Hydrochloride (Fluoxetine)

Fluoxetine Hydrochloride (Fluoxetine)

Manufacturer: REMEDYREPACK INC.

Presentation: CAPSULE

Strength: 40 mg/1

Pack Size:

Metoprolol Succinate (Metoprolol Succinate)

Metoprolol Succinate (Metoprolol Succinate)

Manufacturer: REMEDYREPACK INC.

Presentation: TABLET, EXTENDED RELEASE

Strength: 25 mg/1

Pack Size:

Losartan Potassium (Losartan Potassium)

Losartan Potassium (Losartan Potassium)

Manufacturer: REMEDYREPACK INC.

Presentation: TABLET, FILM COATED

Strength: 25 mg/1

Pack Size:

Browse Our Services And Processes

Comparator Sourcing for Clinical Trials

Comparator Sourcing for Clinical Trials

GNH India brings over 10 years of experience in Comparator

Read More

Name Patient Supply

Name Patient Supply

Today, the exact cause for many rare diseases remains unknown

Read More

Validated Cold Chain Shipment

Validated Cold Chain Shipment

With shifting of pharma industry from synthetic molecules to biologic

Read More

Clinical Trials Supply

Clinical Trials Supply

STOP SOURCING..... START SMART SOURCING...... COME STRAIGHT TO THE SOURCE

Read More

Pharmaceutical Contract Manufacturing

Pharmaceutical Contract Manufacturing

GNH Provides Contract Manufacturing services for: Generic Medicines with following

Read More

Pricing

Pricing

PRICING POLICY Terms of sales are typically prepaid, unless otherwise

Read More

Disclaimer

Please see the Legal Notice for detailed terms and disclaimers. The Legal Notice governs the use of this Website and by accessing and using this Website you agree to be bound by and accept the Legal Notice.

Browse from other international pharmaceuticals

General

64020 Products

GNH India Brings to over 64036 Product SKUs from India all at 1 place with easy access and global deliveries.

US NDC

71245 Products

GNH India Brings to over 71252 Product SKUs from India all at 1 place with easy access and global deliveries.

Canadian DIN

51046 Products

GNH India Brings to over 51047 Product SKUs from India all at 1 place with easy access and global deliveries.

Swiss Drugs

150 Products

GNH India Brings to over 150 Product SKUs from India all at 1 place with easy access and global deliveries.

NZ Drugs

13296 Products

GNH Brings to over 13298 Product SKUs from India all at 1 place with easy access and global deliveries.

FAQ

Check out our delivery process

Can’t find what
you’re looking for?

Contact US
Get Price

Are you an existing customer or a vendor of GNH India? Log in here to

View your Transaction
COMPANY
SERVICES
QUICK LINKS
CONTACT US
Registered Office Address:

Unit # G- 14, 15, 16, 17, Ground Floor, Prabhadevi Industrial Estate, Enterprises Industrial Premises, 408, Veer Sawarkar Road, Prabhadevi,
Mumbai 400025 India

US Office Address:

GNH Pharmaceuticals USA LLC,
Suite E # 499, 1235 EAST BLVD,
Charlotte, NC, 28203, U.S.A
TEL: +1 704 557 0412

Pharmexcil
DB
FIEO-2016
SiteLock

Copyright © 2024 GNHIndia .com. All Rights Reserved. Please read Legal Notice for further details.

Disclaimer: Product names, logos, brands and other trademarks featured or referred to are the property of their respective trademark holders.